AMENDMENTS TO THE CLAIMS

Claims 1-30 (cancelled).

Claim 31 (currently amended): A method of identifying an organic or an inorganic molecule that binds specifically to MN's cell adhesion site, to which site vertebrate cells adhere in a cell adhesion assay, wherein said site is within MN's proteoglycan-like domain, ~~the amino acid sequence of MN's proteoglycan like domain being that of SEQ ID NO: 50,~~ and ~~wherein said site's amino acid sequence consists of an amino acid sequence from said SEQ ID NO: 50,~~ wherein said site's amino acid sequence comprises an amino acid sequence selected from **the group consisting of** SEQ ID NOS: 10 and 98-103, said method comprising testing an organic or an inorganic molecule in a cell adhesion assay, wherein said cell adhesion assay comprises:

(a) allowing MN protein, which comprises said site, and/or MN polypeptide, which comprises said site, to bind to a substrate, to which substrate vertebrate cells do not bind;

(b) rinsing unbound MN protein or unbound MN polypeptide from said substrate;

(c) incubating the bound MN protein or the bound MN polypeptide with said organic or inorganic molecule, and with said vertebrate cells;

(d) rinsing unbound vertebrate cells from said bound MN protein or bound MN polypeptide; and

(e) ~~identifying whether~~ **if** said organic or said inorganic molecule inhibits the adhesion of said vertebrate cells to said MN protein or to said MN polypeptide**, identifying said molecule as** [[by]] specifically binding to said site;

wherein said **site, and said** MN protein or said MN polypeptide**,** [[is]] **are** specifically bound by the M75 monoclonal antibody that is secreted from the hybridoma VU-M75, which was deposited at the American Type Culture Collection under ATCC No. HB 11128, and **wherein said MN protein or said MN polypeptide** is encoded by a ~~nucleic acid whose~~ nucleotide sequence [[is]] selected from the group consisting of:

(i) SEQ ID NO: 1;

(ii) nucleotide sequences that hybridize specifically under stringent hybridization conditions of 0.02 M to 0.15 M NaCl at temperatures of 50°C to 70°C to the complement of SEQ ID NO: 1; and

(iii) nucleotide sequences that differ from SEQ ID NO: 1 or from the nucleotide sequences of (ii) in codon sequence due to the degeneracy of the genetic code**;**

and wherein if said MN protein or said MN polypeptide is a fusion protein or a fusion polypeptide, the non-MN portion

of said fusion protein or said fusion polypeptide does not contain a cell adhesion site.

Claim 32 (previously presented): The method of Claim 31 wherein said molecule is organic.

Claim 33 (previously presented): The method of Claim 31 wherein said molecule is inorganic.

Claim 34 (previously presented): The method of Claim 32 wherein said molecule is a protein or a polypeptide.

Claim 35 (previously presented): The method of Claim 34 wherein said protein or polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 137 and 138.

Claim 36 (previously presented): The method of Claim 34 wherein said polypeptide is selected from the group consisting of SEQ ID NOS: 137 and 138.

Claim 37 (previously presented): The method of Claim 31 wherein said organic or inorganic molecule, when in contact

with a vertebrate preneoplastic or neoplastic cell that abnormally expresses MN protein, inhibits the growth of said cell.

Claim 38 (cancelled).

Claim 39 (previously presented): The method of Claim 31 wherein said MN polypeptide is SEQ ID NO: 106.

Claim 40 (cancelled).

Claim 41 (previously presented): The method of Claim 31 wherein said vertebrate cells are mammalian cells.

Claim 42 (previously presented): The method of Claim 31 wherein said vertebrate cells are human cells.

Claims 43 and 44 (canceled).